These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 28604143)
1. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143 [TBL] [Abstract][Full Text] [Related]
2. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects. Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460 [TBL] [Abstract][Full Text] [Related]
3. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. Xu J; Ren X; Guo T; Sun X; Chen X; Patterson LH; Li H; Zhang J Eur J Pharm Sci; 2019 Oct; 138():105034. PubMed ID: 31382032 [TBL] [Abstract][Full Text] [Related]
4. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652 [TBL] [Abstract][Full Text] [Related]
5. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models. Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291 [TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model. Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389 [TBL] [Abstract][Full Text] [Related]
7. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy. Hu Z; Zheng B; Xu J; Gao S; Lu W Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791 [TBL] [Abstract][Full Text] [Related]
9. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy. Wang X; Yan B; Li H; Yuan J; Guo J; Wang S; Dai P; Liu X ACS Appl Mater Interfaces; 2024 Jun; 16(24):30671-30684. PubMed ID: 38843203 [TBL] [Abstract][Full Text] [Related]
10. Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death. Yang C; He B; Zheng Q; Wang D; Qin M; Zhang H; Dai W; Zhang Q; Meng X; Wang X Nanomedicine (Lond); 2019 Sep; 14(18):2423-2440. PubMed ID: 31549585 [No Abstract] [Full Text] [Related]
11. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548 [TBL] [Abstract][Full Text] [Related]
12. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1. Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737 [TBL] [Abstract][Full Text] [Related]
13. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064 [TBL] [Abstract][Full Text] [Related]
14. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma. Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838 [TBL] [Abstract][Full Text] [Related]
15. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Chen Y; Xia R; Huang Y; Zhao W; Li J; Zhang X; Wang P; Venkataramanan R; Fan J; Xie W; Ma X; Lu B; Li S Nat Commun; 2016 Nov; 7():13443. PubMed ID: 27819653 [TBL] [Abstract][Full Text] [Related]
16. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice. Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351 [TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227 [TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation. Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463 [TBL] [Abstract][Full Text] [Related]
19. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005 [TBL] [Abstract][Full Text] [Related]
20. Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma. Jiang GM; Xie WY; Wang HS; Du J; Wu BP; Xu W; Liu HF; Xiao P; Liu ZG; Li HY; Liu SQ; Yin WJ; Zhang QG; Liang JP; Huang HJ Oncotarget; 2015 Sep; 6(28):25932-42. PubMed ID: 26305550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]